



MHRA

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

Ms Jennifer Boston
NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST
RESEARCH & INNOVATION,
QUEEN'S MEDICAL CENTRE, DERBY ROAD
NOTTINGHAM
NG7 2UH
UNITED KINGDOM

11/09/2023

Dear Ms Jennifer Boston

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our Reference:	CTA 19162/0239/001-0002
IRAS ID:	1004870
Product:	Mannitol
Protocol number:	22SR001
Substantial Amendment Code Number:	SA_01_23

NOTICE OF ACCEPTANCE OF AMENDMENT

I am writing to inform you that the Licensing Authority, having reviewed your application in collaboration with the Research Ethics Committee (where applicable), accepts the proposed amendment to your clinical trial authorisation (CTA), received on 07/08/2023.

COMBINED REVIEW SCIENTIFIC

This amendment may therefore be made.

If applicable, you should ensure your trial details have been updated on the database where you have registered your trial.

You are reminded that where it is appropriate, the Ethics Committee should also be notified of amendments.

You are reminded that from 1 January 2022 you will need to comply with the requirements specified in the following guidance, where applicable:

Import of IMPs from listed countries to GB:

<https://www.gov.uk/government/publications/importing-investigational-medicinal-products-into-great-britain-from-approved-countries>

Supply of IMPs to Northern Ireland:

<https://www.gov.uk/guidance/supplying-investigational-medicinal-products-to-northern-ireland>

Substantial amendments to clinical trials:

<https://www.gov.uk/guidance/guidance-on-substantial-amendments-to-a-clinical-trial>



Medicines & Healthcare products
Regulatory Agency



Any required substantial amendment to your Clinical Trial Authorisation should be submitted and approved as soon as possible and before 1 January 2022.

Yours sincerely,

**Clinical Trials Unit
MHRA**